Results 51 to 60 of about 11,617 (148)

Early high‐dose aflibercept 8 mg clinical outcomes in wet age‐related macular degeneration patients resistant to aflibercept 2 mg or faricimab

Acta Ophthalmologica, EarlyView.
Pinja Sutinen, Idan Hecht, Raimo Tuuminen   +2 more
wiley   +1 more source

Primary Tumor‐Associated Loss of the Y Chromosome and Clinical Outcome in Metastatic Colorectal Cancer

Genes, Chromosomes and Cancer, Volume 65, Issue 6, June 2026.
ABSTRACT Background Alterations of the Y chromosome are frequent events in solid tumors, yet their biological and clinical significance remains incompletely understood. In colorectal cancer (CRC), recent studies have suggested context‐dependent roles of Y‐linked genes in tumor progression, while the impact of tumor‐associated loss of the Y chromosome ...
Anaëlle Isnard, Marie Decraecker, Benjamin Fernandez, Denis Smith, Pierre Dubus, Sandrine Dabernat, Olivier Mansier, Samuel Amintas   +7 more
wiley   +1 more source

Aflibercept as a second-line therapy in metastatic colorectal cancer: A limited Indian experience

Journal of the Scientific Society, 2016
Introduction: Aflibercept in combination with FOLFIRI has been shown to improve overall survival in the pivotal VELOUR study. Aflibercept has not yet been marketed in India.
Govind Babu, Umesh Das, Kuntejowdahalli Lakshmaiah, Lokanatha Dasappa, Linu Abraham Jacob, Suresh Babu   +5 more
doaj   +1 more source

Treatment of Retinitis Pigmentosa-Associated Cystoid Macular Oedema Using Intravitreal Aflibercept (Eylea) despite Minimal Response to Ranibizumab (Lucentis): A Case Report

Case Reports in Ophthalmology, 2016
Background: We present an interesting case of bilateral retinitis pigmentosa (RP)-associated cystoid macular oedema that responded on two separate occasions to intravitreal injections of aflibercept, despite previously demonstrating only minimal response
Stacey A. Strong, Avinash Gurbaxani, Michel Michaelides   +2 more
doaj   +1 more source

Analytical Characterization for Similarity Assessment Between an Aflibercept Biosimilar SB15 and Reference Product (Eylea®)

Ophthalmology and Therapy
Introduction SB15 is a proposed biosimilar product of reference aflibercept (Eylea®), an approved biological drug product for retinal diseases including neovascular age-related macular degeneration (nAMD).
Hangyeore Lee, Jongcheol Huh, Dayoung Kim, Soye Lee, Jaeil Lee, Jungmin Lee, Beom Chan Kim, Jinsu Song   +7 more
doaj   +1 more source

Efficacy, Safety, and Treatment Burden of Aflibercept 2 mg and Ranibizumab in Retinal Vein Occlusion: A Systematic Review and Meta-analysis

Ophthalmology and Therapy
Introduction This systematic review and meta-analysis aimed to provide an updated evidence base for clinical decision-making by comparing the efficacy and safety of aflibercept 2 mg and ranibizumab in treating retinal vein occlusion (RVO).
Jing Wu, Xiaoning He, Fang Qi, Zhan Zhao, Zhe Xu, Hong Yan   +5 more
doaj   +1 more source

Switching to Faricimab or High‐Dose Aflibercept for Neovascular AMD in High‐Demand Patients: Impact on Injection Interval in a Real‐World Cohort

Clinical &Experimental Ophthalmology, Volume 54, Issue 5, Page 724-726, July 2026.
Zachary George Angus, Yin‐Zhi Lee, Sukhpal Singh Sandhu, Robyn Troutbeck, Jonathan Yeoh, Daniel Chiu, Manishka Jayasundera, Jaesser Tan, Sanjeewa Wickremasinghe   +8 more
wiley   +1 more source

The clinical utility of aflibercept for diabetic macular edema

Diabetes, Metabolic Syndrome and Obesity, 2015
Michael W StewartDepartment of Ophthalmology, Mayo School of Medicine, Jacksonville, FL, USAAbstract: The treatment of center-involving diabetic macular edema (DME) has improved because of the proven efficacy of drugs that inhibit the effects of vascular
Stewart MW
doaj  

One-Month Real-World Comparison of Aflibercept 8 mg Versus 2 mg in Treatment-Naïve and Previously Treated Eyes with Neovascular Age-Related Macular Degeneration

Biologics
Background/Objectives: The relative efficacy of 8 mg aflibercept compared to 2 mg in treating neovascular age-related macular degeneration (nAMD) has not been fully established. This study aims to compare the visual and anatomical outcomes of aflibercept
Takahiro Mizukami, Satoru Ueno, Soichiro Mishima, Yoshikazu Shimomura   +3 more
doaj   +1 more source

Deep learning-assisted analysis of biomarker changes after increase of dosing from aflibercept 2 mg to 8 mg in therapy-resistant neovascular age-related macular degeneration

BMJ Open Ophthalmology
Purpose Age-related macular degeneration (AMD) remains the leading cause of blindness in developed countries. There are many different intravitreal anti-vascular endothelial growth factor (VEGF) drugs available for the treatment of neovascular AMD (nAMD).
Siegfried Priglinger, Jakob Siedlecki, Benedikt Schworm, Franziska Eckardt, Michael Hafner, Ben Asani, Caspar Liesenhoff, Alexander Kufner, Johannes Benedikt Schiefelbein   +8 more
doaj   +1 more source